Last edition
News about
Breckenridge Launches Everolimus Tablets, 1mg, generic version of Zortress
Breckenridge Pharmaceutical has announced the launch of Everolimus Tablets, 1 mg, the generic equivalent of Zortress. An mTOR inhibitor immunosuppressant, Everolimus is indicated for the prevention of organ rejection in adult kidney and liver transplant patients and will be available through retail, mail-order pharmacies, and clinics.
Boehringer Ingelheim Acquires Licence from Kyowa Kirin to Develop Treatment for Autoimmune Diseases
Boehringer Ingelheim has acquired a licence from Kyowa Kirin to develop a small molecule programme targeting autoimmune diseases. The collaboration aims to address significant unmet medical needs and strengthen Boehringer’s pipeline of innovative therapies for patients with inflammatory and immune-related conditions.
Cipla Elevates Achin Gupta as Next Managing Director and Global CEO
Cipla has announced the elevation of Achin Gupta as its next Managing Director and Global Chief Executive Officer, effective April 1, 2026. Currently serving as the company’s Global Chief Operating Officer, Gupta will take over from Umang Vohra, who will step down upon completion of his term on March 31, 2026.
ModeX and Regeneron Partner to Develop Multispecific Antibodies
ModeX Therapeutics has entered into a research collaboration with Regeneron to develop multispecific antibodies capable of targeting multiple biological pathways within a single molecule. The partnership, valued at over USD 1 Billion, if multiple assets advance, aims to accelerate innovation across select therapeutic areas.
LillyDirect and Walmart Pharmacy Launch Retail Pick-Up for Zepbound at DTC Pricing
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials.
Roche Receives CE Mark for Elecsys Dengue Antigen Test, Enhancing Global Diagnostic Capabilities
This milestone represents a significant advancement in efficiency and reliability for laboratories worldwide, helping healthcare systems address the escalating global dengue crisis.
Avvio Medical Inc, a clinical-stage medical device company developing advanced kidney stone treatment technologies, has announced that the USA Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to its Enhanced Lithotripsy System (ELS).
EU Approves KEYTRUDA for PD-L1+ Resectable Head and Neck Cancer
KEYTRUDA monotherapy has been approved for use as a neoadjuvant treatment, followed by adjuvant therapy in combination with radiotherapy with or without cisplatin, and continued thereafter as maintenance monotherapy.
CEPI, SII and Oxford University Collaborate to Develop Nipah Virus Vaccine Reserve
CEPI, the Serum Institute of India, and the University of Oxford have partnered to produce ChAdOx1 NipahB vaccine doses for Phase II trials and an investigational reserve of up to 100,000 doses, ready for rapid deployment in case of a future Nipah outbreak.
GSK Raises 2025 Outlook as Cancer and HIV Drug Sales Surge
Despite a significant fall in USA sales of its shingles vaccine, Shingrix, GSK shares climbed to their highest level since May 2024, rising as much as 4.3 per cent. The stock has already advanced about 25 per cent this year.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy